Law Offices of Frank R. Cruz Encourages Navan, Inc. (NAVN) Shareholders To Inquire About Securities Fraud Class ActionFeb 26, 2026 12:06 PM Eastern Standard Time# Law Offices of Frank R. Cruz Encourages Navan, Inc. (NAVN) Shareholders To Inquire About Securities Fraud Class ActionShare---LOS ANGELES-- ([BUSINESS WIRE])-- [The Law Offices of Frank R. Cruz] announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Navan, Inc. ("Navan†or the "Company†) ...

investigation on behalf of GoDaddy Inc. ("GoDaddy†or the "Company†) (NYSE: GDDY) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN GODADDY INC. (GDDY), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsm...[Back to Newsroom] Deadline Approaching: Navan, Inc. (NAVN) Shareholders Who Lost Mon ...

Core Viewpoint - The article discusses a class action lawsuit against uniQure N.V. related to alleged securities fraud, with a deadline for investors to seek lead plaintiff status by April 13, 2026 [1]. Summary by Sections Lawsuit Details - The lawsuit is on behalf of investors who purchased uniQure securities between September 24, 2025, and October 31, 2025 [1]. - Allegations include that the design of uniQure's Pivotal Study was not fully approved by the FDA and that the company downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline due to additional studies [1]. Company Disclosure - On November 3, 2025, uniQure disclosed that the FDA no longer agreed that data from Phase I/II studies of AMT-130 would be adequate for BLA submission, leading to uncertainty regarding the BLA submission timeline [1]. - Following this disclosure, uniQure's share price fell by $33.40, approximately 49.33%, from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [1].

Rosen Law Firm Urges Oracle Corporation (NYSE: ORCL) Stockholders to Contact the Firm for Information About Their RightsFeb 20, 2026 1:45 PM Eastern Standard Time# Rosen Law Firm Urges Oracle Corporation (NYSE: ORCL) Stockholders to Contact the Firm for Information About Their RightsShare---NEW YORK-- ([BUSINESS WIRE])--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Oracle Corporation (NYSE: ORCL) between June 12, 2025, and Dece ...

Core Viewpoint - Inovio Pharmaceuticals, Inc. is facing a class action lawsuit due to alleged securities fraud, with a deadline for shareholders to file a lead plaintiff motion by April 7, 2026. The lawsuit claims that the company made misleading statements regarding its product development and regulatory prospects, leading to significant stock price declines [1]. Summary by Relevant Sections Company Performance - Inovio's stock price fell by $0.27 (3.1%) to close at $8.44 per share on August 9, 2024, following the announcement of a delay in submitting the Biologics License Application (BLA) for INO-3107 due to manufacturing issues [1]. - On December 29, 2025, the stock price dropped by $0.56 (24.45%) to close at $1.73 per share after the FDA accepted the INO-3107 BLA on a standard review timeline instead of the anticipated accelerated review [1]. Legal Proceedings - The class action lawsuit alleges that Inovio's management made materially false and misleading statements and failed to disclose adverse facts about the company's operations and prospects during the class period from October 10, 2023, to December 26, 2025 [1]. - Specific allegations include deficiencies in the manufacturing of Inovio's CELLECTRA device, the unlikelihood of timely BLA submission, and overstated regulatory and commercial prospects for INO-3107 [1]. Investor Actions - Shareholders who suffered losses during the class period are encouraged to contact Glancy Prongay Wolke & Rotter LLP to potentially pursue claims under federal securities laws [1].

Enphase Energy, Inc. Notice of April 20, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application DeadlineFeb 20, 2026 11:58 AM Eastern Standard Time# Enphase Energy, Inc. Notice of April 20, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application DeadlineShare---NEW YORK & NEW ORLEANS--([BUSINESS WIRE])-- [Kahn Swick & Foti], LLC ("KSF†) and KSF partner, former Attorney G ...

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims for Grail, Inc. investors regarding losses that may be recoverable under federal securities laws following the company's failure to meet clinical trial endpoints [1][1]. Group 1: Investigation Details - The investigation focuses on Grail's executive officers and their compliance with federal securities laws [1]. - Grail disclosed on February 19, 2026, that its NHS-Galleri trial did not achieve its primary clinical endpoint, leading to a significant decline of approximately 48% in share price during after-hours trading [1][1]. Group 2: Investor Information - Investors who purchased Grail securities and suffered losses are encouraged to join the investigation without any cost or obligation [1]. - Contact information for inquiries includes Jim Baker at (619) 814-4471 or via email [1]. Group 3: Johnson Fistel Overview - Johnson Fistel, PLLP is a nationally recognized law firm specializing in shareholder rights and securities class action lawsuits, with a history of recovering approximately $90.725 million for clients [1][1]. - The firm has been ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services in 2024, marking its eighth recognition as a top plaintiffs' securities law firm in the U.S. [1].

Core Viewpoint - Kahn Swick & Foti, LLC is investigating the proposed sale of Masimo Corporation to Danaher Corporation, focusing on the adequacy of the $180.00 cash offer per share for Masimo shareholders [1] Company Overview - Masimo Corporation is set to be acquired by Danaher Corporation under a proposed transaction where shareholders will receive $180.00 in cash for each share they own [1] Investigation Details - The law firm Kahn Swick & Foti, LLC, led by former Louisiana Attorney General Charles C. Foti, Jr., is assessing whether the sale price adequately reflects the value of Masimo Corporation and the process leading to this valuation [1]

Core Viewpoint - Klarna Group plc is facing a securities fraud class action lawsuit due to significant losses incurred by investors following its IPO and subsequent financial disclosures that revealed a substantial increase in credit loss provisions [1] Group 1: Company Overview - Klarna Group plc conducted its IPO on September 10, 2025, selling 34.3 million shares at $40 per share [1] - Following the IPO, the company's stock price has significantly declined, closing at $31.63 per share on November 18, 2025, after a 9.3% drop due to negative financial results [1] Group 2: Financial Performance - In its third quarter 2025 financial results, Klarna reported a 39% increase in its provision for credit losses, attributed to changes in market and product mix, particularly an increased share of the U.S. market in its Gross Merchandise Volume (GMV) [1] Group 3: Legal Proceedings - The class action lawsuit alleges that Klarna's management made materially false and misleading statements regarding the company's business and operations, particularly underestimating the risk of increased loss reserves shortly after the IPO [1] - Investors who acquired Klarna securities in connection with the IPO have until February 20, 2026, to seek appointment as lead plaintiffs in the lawsuit [1]

Core Viewpoint - Halper Sadeh LLC is investigating whether Masimo Corporation is obtaining a fair price for its shareholders in the proposed sale to Danaher Corporation for $180.00 per share in cash [1]. Group 1: Investigation Details - The investigation focuses on whether Masimo and its board of directors violated federal securities laws and/or breached fiduciary duties by failing to obtain the best possible price for shareholders [1]. - Concerns include the fairness of the sales process and potential conflicts of interest that may limit superior competing offers [1]. - Halper Sadeh LLC may seek increased consideration, additional disclosures, or other relief and benefits for shareholders [1]. Group 2: Legal Representation - Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, recovering millions on behalf of defrauded investors [1]. - The firm operates on a contingent fee basis, meaning shareholders would not be responsible for out-of-pocket legal fees or expenses [1].